Enzon Pharmaceuticals IncOTCQX US:ENZN
- LAST PRICE0.0711
- TODAY'S CHANGE (%)-0.0009 (-1.2500%)
- Bid / Lots0.0625/ 100
- Ask / Lots0.3395/ 25
- Open / Previous Close0.0711 / 0.0720
- Day Range
- 52 Week Range
- Volume4,050
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENZN |
|---|---|---|
| 03:19 ET | 4000 | 0.0711 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enzon Pharmaceuticals Inc | 5.3M | 21.4x | -60.21% |
Carmell Corp | 5.2M | -0.2x | --- |
Clearmind Medicine Inc | 5.4M | -0.1x | --- |
Klotho Neurosciences Inc | 5.6M | -14.5x | --- |
Aptevo Therapeutics Inc | 4.9M | 0.0x | --- |
Raphael Pharmaceutical Inc | 4.9M | -4.9x | --- |
Company Information
Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.
Contact Information
- Headquarters
- 20 Commerce Drive, Suite 135CRANFORD, NJ, United States 07016
- Phone
- 732-980-4500
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Randolph Read
- Chief Executive Officer, Chief Financial Officer, Secretary
- Richard Feinstein
- Independent Director
- Jordan Bleznick
- Independent Director
- Jaffery Firestone
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.3M |
|---|---|
Revenue (TTM) | $26.0K |
Shares Outstanding | 74.2M |
Enzon Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.51 |
EPS | $0.00 |
Book Value | $0.62 |
P/E Ratio | 21.4x |
Price/Sales (TTM) | 202.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,684.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
